Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Top Page
Tenaya Therapeutics
(NASDAQ:TNYA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.60
▼(-54.81% Downside)
Action:ReiteratedDate:03/31/26
The score is driven primarily by very weak fundamentals (no revenue, large losses, and negative free cash flow) and bearish technicals (trading below all major moving averages with weak momentum). Corporate events are mixed, with partnership upside partially offset by Nasdaq compliance risk; valuation provides limited support due to a negative P/E and no dividend.
Positive Factors
Strategic collaboration with Alnylam
The deal provides near-term non-dilutive funding and large contingent milestone upside while Alnylam assumes downstream development and commercialization costs. This validates Tenaya’s discovery capabilities, reduces capital intensity for late-stage work, and preserves runway to focus on platform research.
Negative Factors
No revenue and persistent net losses
Lack of product revenue means the company remains wholly pre-revenue and dependent on external capital. Ongoing sizable net losses deplete equity and constrain reinvestment, increasing the likelihood of future financings that can dilute shareholders and alter strategic priorities.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic collaboration with Alnylam
The deal provides near-term non-dilutive funding and large contingent milestone upside while Alnylam assumes downstream development and commercialization costs. This validates Tenaya’s discovery capabilities, reduces capital intensity for late-stage work, and preserves runway to focus on platform research.
Read all positive factors
Tenaya Therapeutics (TNYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$155.22M
Dividend YieldN/A
Average Volume (3M)4.00M
Price to Earnings (P/E)―
Beta (1Y)2.42
Revenue GrowthN/A
EPS Growth46.68%
CountryUS
Employees97
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.12
Shares Outstanding216,998,870
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$4.75Price Target Upside257.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Tenaya Therapeutics Business Overview & Revenue Model
Company Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The com...
How the Company Makes Money
Tenaya Therapeutics is a clinical-stage biotechnology company; specific, consistent product-based commercial revenue is not publicly available in the provided context, and the company has historically operated primarily by funding R&D through exte...
Tenaya Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.44M | -8.47M | -8.69M | -8.71M | -4.03M |
| EBITDA | -84.89M | -102.66M | -115.40M | -114.95M | -68.70M |
| Net Income | -90.60M | -111.13M | -124.08M | -123.67M | -72.72M |
Balance Sheet | |||||
| Total Assets | 146.92M | 119.94M | 170.51M | 278.94M | 316.65M |
| Cash, Cash Equivalents and Short-Term Investments | 100.55M | 61.45M | 104.64M | 186.53M | 251.30M |
| Total Debt | 10.83M | 13.61M | 12.42M | 15.10M | 15.70M |
| Total Liabilities | 23.66M | 27.09M | 31.09M | 35.57M | 38.12M |
| Stockholders Equity | 123.27M | 92.85M | 139.42M | 243.38M | 278.53M |
Cash Flow | |||||
| Free Cash Flow | -68.88M | -91.53M | -103.31M | -125.05M | -85.93M |
| Operating Cash Flow | -68.26M | -90.50M | -102.07M | -104.42M | -60.81M |
| Investing Cash Flow | 56.08M | 1.13M | 48.72M | 83.65M | -238.56M |
| Financing Cash Flow | 108.41M | 47.75M | 4.05M | 77.77M | 208.97M |
Tenaya Therapeutics Technical Analysis
Positive
1.33
Price Trends
0.73
Positive
0.83
Negative
1.02
Negative
Market Momentum
-0.01
Negative
51.94
Neutral
58.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNYA, the sentiment is Positive. The current price of 1.33 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.73, and above the 200-day MA of 1.02, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 58.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNYA.
Tenaya Therapeutics Risk Analysis
Tenaya Therapeutics disclosed 70 risk factors in its most recent earnings report. Tenaya Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tenaya Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $562.55M | -5.15 | -26.87% | ― | ― | 60.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $288.67M | 3.92 | 53.18% | ― | ― | ― | |
47 Neutral | $228.86M | -1.93 | -51.35% | ― | -80.88% | -388.61% | |
47 Neutral | $356.71M | -2.63 | -51.44% | ― | ― | 68.53% | |
44 Neutral | $155.22M | -1.20 | -85.20% | ― | ― | 46.68% | |
43 Neutral | $154.69M | -8.62 | 25.65% | ― | ― | 18.82% |
* Healthcare Sector Average
TNYA
Tenaya Therapeutics
0.74
0.28
60.30%
GALT
Galectin Therapeutics
2.47
1.10
80.29%
ABEO
Abeona Therapeutics
5.19
0.34
7.01%
VYGR
Voyager Therapeutics
3.94
0.81
25.88%
TECX
Tectonic Therapeutic
29.95
12.39
70.56%
CADL
Candel Therapeutics
5.10
0.57
12.58%
Tenaya Therapeutics Corporate Events
Business Operations and Strategy
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration
Positive
Mar 5, 2026
On March 4, 2026, Tenaya Therapeutics entered into a collaboration agreement with Alnylam Pharmaceuticals to jointly discover and validate up to 15 novel gene targets for potential cardiovascular disease treatments over an initial 24‑month r...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan
Negative
Jan 30, 2026
On January 28, 2026, Tenaya Therapeutics disclosed that it had received a deficiency notice from Nasdaq after its common stock traded below the required $1.00 minimum bid price for 30 consecutive business days between December 12, 2025, and Januar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.